Your browser doesn't support javascript.
loading
Recent advances in the discovery and development of glyoxalase I inhibitors.
Jin, Tian; Zhao, Lu; Wang, Hong-Ping; Huang, Mao-Lin; Yue, Yan; Lu, Chichong; Zheng, Zhe-Bin.
Afiliación
  • Jin T; Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu 610052, People's Republic of China. Electronic address: jintian@cdu.edu.cn.
  • Zhao L; Sichuan Institute for Food and Drug Control, Chengdu 611731, People's Republic of China. Electronic address: zhaolu0309@126.com.
  • Wang HP; Sichuan Institute for Food and Drug Control, Chengdu 611731, People's Republic of China.
  • Huang ML; Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu 610052, People's Republic of China.
  • Yue Y; Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu 610052, People's Republic of China.
  • Lu C; Department of Chemistry, School of Science, Beijing Technology and Business University, Beijing 100048, People's Republic of China. Electronic address: luchichong@btbu.edu.cn.
  • Zheng ZB; Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu 610052, People's Republic of China. Electronic address: zhebinzheng@hotmail.com.
Bioorg Med Chem ; 28(4): 115243, 2020 02 15.
Article en En | MEDLINE | ID: mdl-31879183
ABSTRACT
Glyoxalase I (GLO1) is a homodimeric Zn2+-metalloenzyme that catalyses the transformation of methylglyoxal (MG) to d-lacate through the intermediate S-d-lactoylglutathione. Growing evidence indicates that GLO1 has been identified as a potential target for the treatment cancer and other diseases. Various inhibitors of GLO1 have been discovered or developed over the past several decades including natural or natural product-based inhibitors, GSH-based inhibitors, non-GSH-based inhibitors, etc. The aim of this review is to summarize recent achievements of concerning discovery, design strategies, as well as pharmacological aspects of GLO1 inhibitors with the target of promoting their development toward clinical application.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Inhibidores Enzimáticos / Desarrollo de Medicamentos / Lactoilglutatión Liasa Límite: Humans Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Inhibidores Enzimáticos / Desarrollo de Medicamentos / Lactoilglutatión Liasa Límite: Humans Idioma: En Revista: Bioorg Med Chem Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2020 Tipo del documento: Article